Response to Wise et al. (Tiotropium safety in real life populations).
نویسندگان
چکیده
Department of Clinical Pharmacology, School of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Philipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Pneumologische Praxis Muenchen – Pasing, Munich, Institute of Health Economics and Management, Ludwig-Maximilians-Universitaet Muenchen, Munich, Helmholtz Zentrum Muenchen – German Research Center for Environmental Health, Member of the German Center for Lung Research, Neuherberg, Institute for Medical Information Sciences, Biometry, and Epidemiology, Ludwig-Maximilians-Universitaet Muenchen, Munich and Diabetes Research Group, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Munich, Germany
منابع مشابه
Tiotropium safety in ‘real‐world’ populations
We read with interest the publication of Schmiedl et al. describing the characteristics of patients treated with tiotropium HandiHaler or Respimat in the Tiotropium Safety and Performance in Respimat (TIOSPIR) study compared with their ‘real-world’ database [1]. The authors noted that patients starting either treatment had similar characteristics but suggest that we may have included a selected...
متن کاملLetter in response to Tashkin et al: Limited generalisability of uplift findings to clinical practice.
We appreciate the comments made by Tashkin et al regarding the limited generalisability of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) findings. In response, the sample we studied was not designed to be representative of the general chronic obstructive pulmonary disease (COPD) population, but rather the subgroup of patients with severe COPD who are likely ...
متن کاملLung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease
Background and purpose While the efficacy and safety of combined tiotropium and olodaterol in patients with COPD was established in a large clinical trial program, it is important to assess whether clinical data can be applied to geographic patient groups, particularly for East Asian patients who may have a different phenotypic profile to the global trial population. This study aimed to compare...
متن کاملThe Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
BACKGROUND Tiotropium bromide is an effective therapy for COPD patients. Comparing across programs tiotropium Respimat Soft Mist inhaler was at least as efficacious as tiotropium HandiHaler, however, concerns have been raised about tiotropium's safety when given via Respimat. METHODS The TIOSPIR trial (NCT01126437) compares the safety and efficacy of tiotropium Respimat 5 μg once daily (marke...
متن کاملUse of tiotropium Respimat versus HandiHaler and mortality in patients with COPD.
VERHAMME et al. [1] recently compared the possible mortality effect of two delivery systems of tiotropium in their Dutch observational cohort study of 11 287 chronic obstructive pulmonary disease (COPD) first-time users of tiotropium in primary care. They concluded that ‘‘until further data become available, physicians should be aware that patients with arrhythmia or a history of cardiovascular...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- British journal of clinical pharmacology
دوره 82 2 شماره
صفحات -
تاریخ انتشار 2016